6.80Open6.80Pre Close0 Volume11 Open Interest2.50Strike Price0.00Turnover439.82%IV26.70%PremiumJan 17, 2025Expiry Date4.84Intrinsic Value100Multiplier24DDays to Expiry1.96Extrinsic Value100Contract SizeAmericanOptions Type0.9355Delta0.0151Gamma1.40Leverage Ratio-0.0218Theta0.0011Rho1.31Eff Leverage0.0024Vega
Vir Biotechnology Stock Discussion
US FDA: Revoked Emergency Use Authorization for GSK and Vir Biotechnology's Sotrovimab as of Dec 13 - Website
*************************************
REVERSE...
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
📊⚡️📊
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
📊⚡️📊
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Phase 3 Eclipse Program to Evaluate Tobevibart and Elebsiran
No comment yet